Enhanced recovery protocol for transoral robotic surgery demonstrates improved analgesia and narcotic use reduction.
Aged
Analgesia
Cohort Studies
Drug Utilization
/ statistics & numerical data
Enhanced Recovery After Surgery
Female
Head and Neck Neoplasms
/ surgery
Humans
Male
Middle Aged
Narcotics
/ administration & dosage
Pain Measurement
/ methods
Pain, Postoperative
/ diagnosis
Prescriptions
/ statistics & numerical data
Retrospective Studies
Robotic Surgical Procedures
/ methods
Treatment Outcome
ERAS
Enhanced recovery after surgery
Head and neck
Opioid
TORS
Trans-oral robotic surgery
Journal
American journal of otolaryngology
ISSN: 1532-818X
Titre abrégé: Am J Otolaryngol
Pays: United States
ID NLM: 8000029
Informations de publication
Date de publication:
Historique:
received:
24
06
2020
accepted:
30
06
2020
pubmed:
28
7
2020
medline:
15
12
2020
entrez:
28
7
2020
Statut:
ppublish
Résumé
No study has evaluated the impact of the Enhanced Recovery After Surgery (ERAS) protocol on opioid usage among patients undergoing transoral robotic surgery (TORS). In this retrospective study, patients undergoing TORS were enrolled in an ERAS protocol and compared to control patients. Primary outcome measures included postoperative mean morphine equivalent dose (MED), Defense and Veterans Pain Rating Scale (DVPRS) pain scores, and opioid prescriptions on discharge. The mean MED administered postoperatively was lower in the ERAS group (17.6 mg) than in the control group (65.0 mg) (p < .001). Average postoperative DVPRS scores were 2.9 in the ERAS group vs. 4.2 in the control group (p = .042). Fewer patients in the ERAS group received opioid prescriptions on discharge (31.6%) than controls (96.2%) (p < .001). The TORS ERAS protocol is associated with reduced postoperative opioid usage, lower pain scores, and reduced opioid requirements on discharge.
Sections du résumé
BACKGROUND
BACKGROUND
No study has evaluated the impact of the Enhanced Recovery After Surgery (ERAS) protocol on opioid usage among patients undergoing transoral robotic surgery (TORS).
METHODS
METHODS
In this retrospective study, patients undergoing TORS were enrolled in an ERAS protocol and compared to control patients. Primary outcome measures included postoperative mean morphine equivalent dose (MED), Defense and Veterans Pain Rating Scale (DVPRS) pain scores, and opioid prescriptions on discharge.
RESULTS
RESULTS
The mean MED administered postoperatively was lower in the ERAS group (17.6 mg) than in the control group (65.0 mg) (p < .001). Average postoperative DVPRS scores were 2.9 in the ERAS group vs. 4.2 in the control group (p = .042). Fewer patients in the ERAS group received opioid prescriptions on discharge (31.6%) than controls (96.2%) (p < .001).
CONCLUSION
CONCLUSIONS
The TORS ERAS protocol is associated with reduced postoperative opioid usage, lower pain scores, and reduced opioid requirements on discharge.
Identifiants
pubmed: 32717682
pii: S0196-0709(20)30343-4
doi: 10.1016/j.amjoto.2020.102649
pii:
doi:
Substances chimiques
Narcotics
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102649Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.